Endocrine Treatment with 2 Years of Tamoxifen versus 2 Years of Exemestane in Postmenopausal Patients with High-Risk Early Breast Cancer and Persisting Circulating Tumor Cells - First Results of the SUCCESS C Endocrine Treatment Sub-Study
Erstveröffentlichung
2018
Wissenschaftlicher Artikel
Published in
Oncology Research and Treatment ; 41 (2018), 3. - S. 93-98. - ISSN 2296-5270. - eISSN 2296-5262